Logo

LG Chem Receives the Korean MFDS’ Approval for Xelenka for the Treatment of Autoimmune Disease

Share this
LG Chem

LG Chem Receives the Korean MFDS’ Approval for Xelenka for the Treatment of Autoimmune Disease

Shots: 

  • The company received marketing authorization from the Korean Ministry of Food and Drug Safety for Xelenka (biosimilar to Humira) for the treatment of autoimmune disorders 
  • LG Chem filed the marketing application with MFDS in Dec 2022. Moreover, this approved is granted for the high concentration of humira which is citrate free 
  • Xelenka like Humira is an Anti-TNF mAb indicated for RA, PA, Uveitis in adults, CD & JIA in children and this a second approval for LG Chem for autoimmune diseases after approval of biosimilar Eucept  

Ref: Korea BioMed Image: LG Chem

Related News:- Intas Pharmaceuticals Entered into a Collaboration and License Agreement with mAbxience for Etanercept Biosimilar to Treat Autoimmune Diseases

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions